NYSEARCA:PHGE - American Stock Exchange - US09090D3017 - Common Stock - Currency: USD
BIOMX INC
NYSEARCA:PHGE (2/4/2025, 8:04:01 PM)
0.7096
-0.03 (-3.46%)
The current stock price of PHGE is 0.7096 USD. In the past month the price decreased by -8.38%. In the past year, price decreased by -68.46%.
NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 ...
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.77 | 335.67B | ||
AMGN | AMGEN INC | 15.04 | 155.36B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
NTRA | NATERA INC | N/A | 23.00B | ||
BIIB | BIOGEN INC | 8.73 | 20.76B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Biomx Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Gaithersburg, Maryland and currently employs 58 full-time employees. The company went IPO on 2018-12-18. BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
BIOMX INC
708 Quince Orchard Rd, Suite 205
Gaithersburg MARYLAND 7414002 US
CEO: Jonathan Solomon
Employees: 65
Company Website: https://www.biomx.com/
Investor Relations: http://ir.biomx.com/
Phone: 18449720500
The current stock price of PHGE is 0.7096 USD.
The exchange symbol of BIOMX INC is PHGE and it is listed on the American Stock Exchange exchange.
PHGE stock is listed on the American Stock Exchange exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PHGE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PHGE.
PHGE does not pay a dividend.
PHGE does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.3).
The outstanding short interest for PHGE is 0.22% of its float.
ChartMill assigns a technical rating of 2 / 10 to PHGE. When comparing the yearly performance of all stocks, PHGE is a bad performer in the overall market: 93.19% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to PHGE. While PHGE seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months PHGE reported a non-GAAP Earnings per Share(EPS) of -5.3. The EPS decreased by 43.62% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.51% | ||
ROE | -22.97% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to PHGE. The Buy consensus is the average rating of analysts ratings from 8 analysts.